

# Report

## Monthly New Drug and First Time Generic

August 2019



### New Drug Pipeline

Medication (Trade Name)	Drug Class	Therapeutic Use	Status Update
Sumatriptan Nasal Spray ( <b>Tosymra™</b> )	Migraine Agent	Migraine Headache Treatment	Launch anticipated by end of 2019. Approved January 25, 2019.
Buprenorphine/Naloxone ( <b>Cassipa®</b> )	Opioid Agonist/Antagonist	Opioid Misuse Disorder	Launch pending. Approved September 7, 2018.
Benzhydrocodone HCl/Acetaminophen ( <b>Apadaz™</b> )	Opioid Analgesic – Immediate Release	Pain	Anticipated second half of 2019. Approved February 23, 2018.
Buprenorphine Depot Injection ( <b>Brixadi™</b> )	Opioid Agonist	Treatment of Opioid Addiction	Tentatively approved December 26, 2018. Anticipated in November 2020 following expiration of exclusivity period for Sublocade™.
Oxycodone ( <b>Loxicodol</b> )	Opioid Analgesic – Extended Release	Pain	FDA review pending.
Oxycodone HCl ( <b>Rexista™</b> )	Opioid Analgesic – Extended Release	Pain	FDA review pending after declining to approve in September 2017.
Naloxone Injection ( <b>Zimhi™</b> )	Opioid Antagonist	Opioid Overdose	FDA expected to review this higher dose of naloxone in a prefilled syringe October 2019.
Lasmiditan	Serotonin 1F Receptor Agonist	Migraine Headache Treatment	FDA expected to review November 2019.
Ubrogepant	CGRP Antagonist	Migraine Headache Treatment	FDA expected to review 4th quarter 2019.
Oxycodone HCl/Naltrexone HCl ( <b>SequestOx™</b> )	Opioid Analgesic – Immediate Release	Pain	FDA declined to approve in July 2016. Expected to review again in 2019.
Oxycodone HCl/Naltrexone HCl ( <b>SequestOx™</b> )	Opioid Analgesic – Immediate Release	Pain	FDA declined to approve in July 2016. Expected to review again in 2019.

### Generic Pipeline

Medication (Trade Name)	Drug Class	Therapeutic Use	Status Update
Hydrocodone Bitartrate ( <b>Zohydro® ER</b> )	Opioid Analgesic – Extended Release	Pain	Generic anticipated fourth quarter 2019.
Meloxicam ( <b>Vivlodex®</b> )	NSAID	Pain	Generic anticipated by end of 2019.
Doxepin ( <b>Silenor®</b> )	Tricyclic Antidepressant	Sleep Disorders	Generic anticipated January 1, 2020.
Naloxone HCl ( <b>Narcan®</b> ) Nasal Spray	Opioid Antidote	Opioid Overdose	Launch pending. Generic approved April 19, 2019.
Emtricitabine/Tenofovir ( <b>Truvada®</b> )	Antiretroviral	HIV Post-Exposure Prophylaxis	Generic anticipated late 2020.
Naloxone HCl ( <b>Narcan®</b> ) Nasal Spray	Opioid Antidote	Opioid Overdose	Launch pending. Generic approved April 19, 2019.

# Report

## Monthly New Drug and First Time Generic

August 2019



### Available in the Last 12 Months

Medication (Trade Name)	Drug Class	Therapeutic Use	Status Update
Solriamfetol ( <b>Sunosi™</b> )	Stimulant	Excessive Sleepiness	July 2019
Meloxicam ( <b>Qmiiz™ ODT</b> )	NSAID	Pain	April 2019
Esketamine Nasal Spray ( <b>Spravato™</b> )	Antidepressant	Treatment Resistant Depression	March 2019
Sufentanil ( <b>Dsuvia™</b> )	Opioid Analgesic – Immediate Release	Pain	February 2019
Cannabidiol ( <b>Epidiolex®</b> )	Cannabinoid	Seizures	November 2018
Galcanezumab-gnlm ( <b>Emgality™</b> )	CGRP Antagonist	Migraine Headache Prophylaxis	October 2018
Lidocaine Transdermal Patch ( <b>ZTlido™</b> )	Topical Analgesic	Nerve Pain	September 2018
Fremanezumab-vfrm ( <b>Ajovy™</b> )	CGRP Antagonist	Migraine Headache Prophylaxis	September 2018

### Newly Available Generics

Pregabalin ( <b>Lyrica®</b> )	Anticonvulsant	Neuropathic Pain	July 2019
Cyclobenzaprine HCl ( <b>Amrix®</b> )	Skeletal Muscle Relaxant	Muscle Spasm	March 2019
Fluticasone/Salmeterol ( <b>Advair Diskus®</b> )	Asthmatic Agent	Asthma and COPD	February 2019
Buprenorphine/Naloxone ( <b>Suboxone®</b> )	Opioid Agonist/Antagonist	Opioid Misuse Disorder	February 2019
Vardenafil ( <b>Levitra®</b> )	Phosphodiesterase Inhibitor	Opioid-induced Erectile Dysfunction	October 2018
Tadalafil ( <b>Cialis®</b> )	Phosphodiesterase Inhibitor	Opioid-induced Erectile Dysfunction	September 2018